ARTV

Artiva Biotherapeutics develops off-the-shelf allogeneic natural killer cell therapies for treating cancer, focusing on creating readily available NK cell treatments that can be manufactured at scale and administered to multiple patients without requiring patient-specific customization. Headquartered in San Diego, California, the company's lead candidate AB-101 represents an allogeneic NK cell therapy engineered to target CD19-expressing cancers including non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. Artiva's platform technology centers on optimizing natural killer cells harvested from healthy donors, expanding them ex vivo, and potentially engineering them with additional capabilities including enhanced tumor recognition, improved persistence in patients, and resistance to immunosuppressive tumor environments. The off-the-shelf approach addresses key limitations of autologous CAR-T therapies which require harvesting immune cells from each individual patient, a time-consuming and expensive manufacturing process potentially delaying treatment for rapidly progressing cancers. Artiva's NK cell therapies can be manufactured in large batches, cryopreserved, stored at treatment centers, and thawed for immediate administration when needed. The company advanced AB-101 into Phase 1b/2a clinical trials evaluating safety, tolerability, and preliminary efficacy in relapsed/refractory B-cell malignancies. Artiva raised approximately $250 million through Series B financing in 2021 and 2022 supporting clinical development, manufacturing scale-up, and pipeline expansion exploring NK cell therapies for solid tumors and additional hematologic malignancies.